FDA Warning: Do Not Use PNC-27 for Treatment or Cure for Cancer

PNC 27 molecule
PNC 27 molecule

The FDA is warning consumers not to buy or use PNC-27, a product promoted and sold through http://PNC27.com, as a treatment or cure for cancer. An FDA laboratory discovered the bacteria Variovorax paradoxus in a PNC-27 solution sample for inhalation.

Consumers who use a contaminated product are at risk for serious, potentially life-threatening infections. Consumers at higher risk include vulnerable populations, such as young children, elderly people, pregnant women, and people with weakened immune systems.

PNC-27 may be available in various dosage forms, such as a nebulized solution, intravenous solution, vaginal suppository, or rectal suppository. FDA has not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer. The agency has not received reports of illnesses or serious adverse events related to PNC-27.

The FDA recommends patients with cancer discuss treatment options with a licensed health care professional. Patients who have used any PNC-27 product and have concerns should contact their health care provider as soon as possible.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program.

The FAQ at the PNC-27 website says, “PNC-27 is a tiny, nontoxic protein molecule that attaches to specific receptors only found on cancer cells, causing them to die.

“PNC is a set of investigational proteins designed to attach to malformed cells and cause them to die via cell necrosis. PNC proteins were theorized, then created using a super computer in New York by Dr. Matthew Pincus and Dr. Joseph Michl of Suny Downstate Medical Center.

“PNC-28 was the first protein investigated, followed by its more effective counterpart, PNC-27. Multiple studies in laboratories and on humans have been successfully conducted. PNC is also the subject of several US Patents.”


Share this Post: